TLR4 antagonists, such as eritoran, which did not show success in phase III clinical trials for sepsis [44], and ApTOLL, which was safe and effective in reducing mortality in human subjects with acute ischemic stroke [45], have been previously tested. The gene discussed is TLR4; the disease is Sepsis.